Genotoxicity of several clinically used topoisomerase II inhibitors

Toxicology Letters

Volumn 116, Issue 1-2, 2000, Pages 7-16

  Boos, Gunther ^a   Stopper, Helga ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Comet assay; L5178Y mouse lymphoma cells; Micronuclei; Topoisomerase II inhibitors

Indexed keywords

2,3 BIS(3,5 DIOXO 1 PIPERAZINYL)BUTANE; AMSACRINE DERIVATIVE; DIMINAZENE ACETURATE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; GENISTEIN; MITOXANTRONE;

ANIMAL CELL; ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA CLEAVAGE; GENOTOXICITY; IN VITRO STUDY; LEUKEMIA L 5178 Y; MICRONUCLEUS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMSACRINE; ANIMALS; COMET ASSAY; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; ETOPOSIDE; MICE; MICRONUCLEI, CHROMOSOME-DEFECTIVE; MUTAGENS; TUMOR CELLS, CULTURED;

EID: 0033922361     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(00)00192-2     Document Type: Article

References (60)

1. Ashby J., Tinwell H., Glover P., Poorman-Allen P., Krehl R., Callander R.D., Clive D. Potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: comparison to Salmonella response. Environ. Mol. Mutagen. 24:1994;51-60.
2. Backer L.C., Allen J.W., Harrington-Brock K., Campbell J.A., DeMarini D.M., Doerr C.L., Howard D.R., Klirerman A.D., Moore M.M. Genotoxicity of inhibitors of DNA topoisomerase I (camptothecin) and topoisomerase II (m-AMSA) in vivo and in vitro. Mutagenesis. 5:1990;541-547.
3. Barnes S., Peterson T.G., Coward L. Rationale for the use of genistein-containing soy matrices in chemoprevention trials for breast and prostate cancer. J. Cell. Biochem. 22(Suppl.):1995;181-187.
4. Bechert T., Diekman S., Arndt-Jovin D.J. Human 170 kDa and 180 kDa topoisomerases II bind preferentially to curved and left-handed linear DNA. J. Biomol. Struc. Dynam. 12:1994;605-623.
5. Belani C.P., Doyle L.A., Aisner J. Etoposide: current status and future prospectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol. 34(Suppl.):1994;118-126.
6. Bell A., Kittler L., Lober G., Zimmer C. DNA binding properties of minor groove binders and their influence on the topoisomerase II cleavage reaction. J. Mol. Recognit. 10:1997;245-255.
7. Burdon D.A., Osheroff N. Mechanism of action of eucaryotic topoisomerase II and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1400:1998;139-154.
8. Burdon D.A., Osheroff N. In vitro evolution of preferred topoisomerase II DNA cleavage site. J. Biol. Chem. 274:1999;5227-5235.
9. Chow K.-C., Macdonald T.L., Ross W.E. DNA binding by epipodophyllotoxins and N-acyl anthracyclines: implications for mechanism of topoisomerase II inhibition. Mol. Pharmacol. 34:1988;467-473.
10. Clive D., Flamm W.G., Machesco M.R., Bernheim N.J. Mutational assay system using the thymidine kinase locus in mouse lymphoma cells. Mutat. Res. 16:1972;77-87.
11. Combes R.D., Stopper H., Caspary W.J. The use of the L5178Y mouse lymphoma cells to assess mutagenic, clstogenic and aneugenic activity of chemicals. Mutagenesis. 10:1995;403-408.
12. Corbett A.H., Osheroff N. When good enzymes go bad: conversion of topoisomerase II to a cellular toxin by antineoplstic drugs. Chem. Res. Toxicol. 6:1993;585-597.
13. Creighton A.M., Hellmann K., Whitecross S. Antitumour activity in a series of bisdikoxopiperazines. Nature. 222:1969;384-385.
14. Crespi M.D., Ivanier S.E., Genovese J., Baldi A. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem. Biophys. Res. Commun. 136:1986;521-528.
15. DeMarini D.M., Doerr C.L., Meyer M.K., Brock K.H., Hozier O., Moore M.M. Mutagenicity of m-AMSA and o-AMSA in mammalian cells due to clastogenic mechanism: possible role of topoisomerase. Mutagenesis. 2:1987;349-355.
16. Doerr C.L., Harrington-Brock K., Moore M.M. Micronucleus, chromosome aberration, and small-colony TK mutant analysis to quantitate chromosomal damage in L5178Y mouse lymphoma cells. Mutation Res. 222:1989;191-203.
17. Ferguson L.F., Baguley B.C. Induction of petite mutants in yeast by non-intercalative DNA-binding antitumor agents. Eur. J. Cancer Clin. Oncol. 19:1983;1575-1583.
18. Gaulden M.E. Hypothesis: some mutagens directly alter specific chromosomal proteins (DNA topooiomerase II and peripheral proteins) to produce chromosome stickiness. Mutagenesis. 2:1987;357-365.
19. Glikin G.C., Jovin T.M., Arndt-Jovin D.J. Interactions of Drosophila DNA topoisomerase II with left-handed Z-DNA in supercoiled minicircles. Nucleic Acids Res. 19:1991;7139-7144.
20. Gupta R.S., Bromke A., Bryant D.W., Gupta R., Singh B., McCalla D.R. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not procaryotic test systems. Mutagenesis. 2:1987;179-186.
21. Hande K.R. Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim. Biophys. Acta. 1400:1998;173-184.
22. Hellmann K., Newton K.A., Whitmore D.N., Hanham I.W.F., Bond J.F. Preliminary clinical assessment of ICRF-159 in acute leukaemia and lymphosarcoma. Br. Med. J. 1:1969;822-824.
23. Howard M.T., Lee M.P., Hsieh T.-S., Griffith J.D. Drosophila topoisomerase II-DNA are affected by DNA structure. J. Mol. Biol. 217:1990;53-62.
24. Hsieh T.S. DNA topoisomerases. Curr. Opin. Cell Biol. 4:1992;396-400.
25. Kallio M., Lahdetie J. Analysis of micronuclei induced in mouse early spermatids by mitomycin C, vinblastine sulfate or etoposide using fluorescence in situ hybridization. Mutagenesis. 8:1993;561-567.
26. Kingma P.S., Burdon D.A., Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. Biochemisty. 38:1999;3457-3461.
27. Kulling S.E., Metzler M. Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food. Chem. Toxicol. 35(6):1997;605-613.
28. Kulling S.E., Rosenberg B., Jacobs E., Metzler M. The phytoestrogens coumoestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. Arch. Toxicol. 73(1):1999;50-54.
29. Manandhar M., Cheng M., Latropoulos M.J., Noble J.F. Genetic toxicology profile of the new antineoplastic drug mitoxantrone in the mammalian test systems. Arzneim. Forsch. 36:1986;1375-1379.
30. Markovits J., Linassier C., Fosse P., Couprie J., Pierre J., Jacqumain-Sablon A., Saucier J.-M., Le Peccq J.-B., Larsen A.K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 49:1989;5111-5117.
31. Miller B.M., Locher F., Seelbach A., Stopper H., Utesch D., Madle S. Evaluation of the in vitro micronucleus test (MNT) as an alternative to the in vitro chromosomal aberration assay: position of the GUM working group 'in vitro MNT'. Mutat. Res. 410:1998;81-116.
32. Müller S.O., Eckert I., Lutz W.K., Stopper H. Genotoxicity of the laxative drug components emodin, aloe-emodin and danthron in mammalian cells: topoisomerase II mediated? Mutat. Res. 371:1996;165-173.
33. Nelson E.M., Tewey K.M., Liu L.F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)-methansulfon-m-aniside. Proc. Natl. Acad. Sci. USA. 81:1984;1361-1364.
34. Nitiss J.L. Roles of DNA topoisomerases in chromosomal replication and segregation. Adv. Pharmacol. 29:1994;103-134.
35. Osheroff N. Eucaryotic topoisomerase II: characterization of enzyme turnover. J. Mol. Biol. 261:1986;9944-9950.
36. Osheroff N. Effect of antineoplastic agents on the DNA cleavage/religation reaction of eucaryotic topoisomerase II: inhibition of DNA religation by etoposide. Biochem. 28:1989;6157-6160.
37. Osheroff N., Shelton E.R., Brutlag D.L. DNA topoisomerase II from Drosophila melanogaster: relaxation of supercoiled DNA. J. Biol. Chem. 258:1983;9536-9543.
38. Osheroff N., Zechierich E.L., Gale K.C. Catalytic function of DNA topoisomerase II. BioEssays. 13:1991;269-275.
39. Perrin D., van Hille B., Hill B.T. Differential sensitivities of recombinant human topoisomerase II alpha and beta to various classes of topoisomerase II-interacting agents. Biochem. Pharmacol. 56:1998;503-507.
40. Poot M., Kausch K., Kohler J., Haaf T., Hoehn H. The minor-groove binding DNA-ligands netropsin, distamycin A and berenil cause polyploidisation via impairment of the G2 phase of the cell cycle. Cell. Struc. Func. 15:1990;151-157.
41. Portugal J. Berenil acts as a poison of eukaryotic topoisomerase II. FEBS Lett. 344:1994;136-138.
42. Woynarowski J.M., Sigmund R.D., Beerman T.A. DNA minor groove binding agents interfere with fopoisomerase II mediated lesions induced by epipodophyllotoxin derivative VM-26 and acridine derivative m-Amsa in nuclei from L1210 cells. Bochem. 28:1989;3850-3855.
43. Record I.R., Jannes M., Dreosti I.E., King R.A. Induction of micronucleus formation in mouse splenocytes by the soy isoflavone genistein in vitro but not in vivo. Food Chem. Toxicol. 33(11):1995;919-922.
44. Robinson M.J., Osheroff N. Effects of antineoplastic drugs on the post-strand passage DNA cleavage/religation equilibrium of topoisomerase II. Biochem. 30:1990;1807-1813.
45. Robinson M.J., Osheroff N. Stabilisation of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino)methanesulfon-m-aniside. Biochem. 29:1991;2511-2515.
46. Roca J., Ishida R., Berger J.M., Andoh T., Wang J.C. Antitumor bisdioxopiperazine inhibit yeast topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc. Natl. Acad. Sci. USA. 91:1994;1781-1785.
47. Sandoval C., Pui C.H., Bowman L.C., Heaton D., Hurwitz S.C., Raimondi S.C., Behm F.G., Head D.R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irridation. J. Clin. Oncol. 11:1993;1039-1045.
48. Singh N.T., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantification of low levels of DNA damage in individual cells. Exp. Cell. Res. 175:1988;184-191.
49. Smith M.A., Rubinstein L., Ungerleider R.S. Theapie-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med. Pediatr. Oncol. 23:1994;86-98.
50. Soerensen B.S., Sinding J., Andersen A.H., Alsner J., Jensen P.B., Westeergaard O. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. J. Mol. Biol. 228:1992;778-786.
51. Stoll B.A. Eating to beat breast cancer: potential role for soy supplements. Ann. Oncol. 8:1997;223-225.
52. Stopper H., Müller S.O. Micronuclei as a biological endpoint for genotoxicity: a minireview. Toxicol. Vitro. 11:1997;661-667.
53. Stopper H., Körber C., Schiffmann D., Caspary W.J. Cell-cycle dependent micronucleus formation and mitotic disturbances induced by 5-azacytidine in mammalian cells. Mutat. Res. 300:1993;165-177.
54. Tanabe K., Ikegami Y., Ishida R., Andoh T. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res. 51:1991;4903-4908.
55. Tidwell R.R., Jones S.K., Geratz J.D., Ohemeng K.A., Cory M., Hall J.E. Analogues of 1,5 Bis(4-Amidinophenoxy)pentane (Pentamidine) in the treatment of experimental Pneumocystis carmii pneumonia. J. Med. Chem. 33:1990;1252-1257.
56. Turner P.R., Denny W.A. The mutagenic properties of DNA minor-groove binding ligands. Mutation Res. 355:1996;141-169.
57. Wang J.C. DNA topoisomerases. Annu. Rev. Biochem. 65:1996;635-692.
58. Raether W., Hajdu P., Seidenath H., Damm D: (1974) Tropenmedizin und Parasitologie 25, 1, 42-48. Pharmacokinetic and chemoprophylactic studies with berenil in macaques (trypanosoma-rhodesiense-infection).
59. Yamashita Y., Kawada S.-Z., Nakano H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonitercalative flavonoids, genistein and orobol. Biochem. Pharmacol. 39:1990;737-744.
60. Zechiedrich E.L., Osheroff N. Eucaryotic topoisomerases recognize nucleic acids topology by preferentially interacting with DNA crossovers. EMBO J. 9:1990;4555-4562.